Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Amivantamab and hyaluronidase-lpuj (human recombinant)

Drug class: Endoglycosidase

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Amivantamab and hyaluronidase-lpuj (human recombinant) key facts

Drug class
Endoglycosidase
Used for
Limitations of use: RYBREVANT FASPRO is not indicated as a treatment for patients with OPSCC that is HPV-associated (i.e., by p16 IHC). (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Latest FDA recall
None listed

Sources: FDA label (November 5, 2026); FDA NDC Directory (November 13, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Amivantamab and hyaluronidase-lpuj (human recombinant) used for?
The FDA-approved label (Rybrevant Faspro, Janssen Biotech, Inc., November 5, 2026) says: “RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Amivantamab and hyaluronidase-lpuj (human recombinant)?
The “Adverse Reactions” section of the FDA label (Rybrevant Faspro, Janssen Biotech, Inc., November 5, 2026) begins: “The following adverse reactions are discussed elsewhere in the labeling: Hypersensitivity and Administration-Related Reactions [see Warnings and Precautions (5.1)] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.2)] Venous Thromboembolic Events with Concomitant Use with Lazertinib [see Warnings and Precautions (5.3)] Dermatologic Adverse Reactions [see Warnings and Precautions (5.4)] Ocular Toxicity [see Warnings and Precautions (5.5)] RYBREVANT FASPRO in Combination with Lazertinib The most common adverse reactions (≥ 20%) were rash, nail toxicity, musculoskeletal pain, fatigue, stomatitis, edema, nausea, diarrhea, vomiting, constipation, decreased appetite, and headache.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Amivantamab and hyaluronidase-lpuj (human recombinant) have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Amivantamab and hyaluronidase-lpuj (human recombinant)?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Amivantamab and hyaluronidase-lpuj (human recombinant) been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Amivantamab and hyaluronidase-lpuj (human recombinant)?
1 company lists prescription products of Amivantamab and hyaluronidase-lpuj (human recombinant) in the FDA NDC Directory, including Janssen Biotech, Inc.

What Amivantamab and hyaluronidase-lpuj (human recombinant) is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. …

— FDA label: Rybrevant Faspro, Janssen Biotech, Inc., effective November 5, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (injection, subcutaneous), Rybrevant Faspro, Janssen Biotech, Inc.; it covers 4 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Amivantamab and hyaluronidase-lpuj (human recombinant) side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following adverse reactions are discussed elsewhere in the labeling: Hypersensitivity and Administration-Related Reactions [see Warnings and Precautions (5.1)] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.2)] Venous Thromboembolic Events with Concomitant Use with Lazertinib [see Warnings and Precautions (5.3)] Dermatologic Adverse Reactions [see Warnings and Precautions (5.4)] Ocular Toxicity [see Warnings and Precautions (5.5)] RYBREVANT FASPRO in Combination with Lazertinib The most common adverse reactions (≥ 20%) were rash, nail toxicity, musculoskeletal pain, fatigue, stomatitis, edema, nausea, diarrhea, vomiting, constipation, decreased appetite, and headache.

Read more of this section

(6.1) The most common Grade 3 or 4 laboratory abnormalities (≥ 2%) were decreased lymphocyte count, decreased sodium, decreased potassium, decreased albumin, increased alanine aminotransferase, increased aspartate aminotransferase, decreased platelet count, increased gamma-glutamyl transferase, and decreased hemoglobin. (6.1) RYBREVANT FASPRO as a Single Agent The most common adverse reactions (≥ 20%) were rash, fatigue, nail toxicity, stomatitis, and edema. (6.1) The most common Grade 3 or 4 laboratory abnormalities (≥ 2%) were decreased lymphocytes, decreased potassium, decreased hemoglobin, increased alanine aminotransferase, decreased albumin, decreased sodium, increased aspartate aminotransferase and decreased white blood cells. (6.1) Intravenous Amivantamab in Combination with Lazertinib The most common adverse reactions (≥ 20%) were rash, nail toxicity, infusion-related reaction, musculoskeletal pain, stomatitis, edema, VTE, paresthesia, fatigue, diarrhea, constipation, COVID-19, hemorrhage, dry skin, decreased appetite, pruritus, and nausea. (6.1) The most common Grade 3 or 4 laboratory abnormalities (≥ 2%) were decreased albumin, decreased sodium, increased ALT, decreased potassium, decreased hemoglobin, increased AST, increased GGT, and increased magnesium. (6.1) Intravenous Amivantamab in Combination with Carboplatin and Pemetrexed The most common adverse reactions (≥ 20%) were rash, nail toxicity, infusion-related reaction, fatigue, nausea, stomatitis, constipation, edema, decreased appetite, musculoskeletal pain, vomiting, and COVID-19. (6.1) The most common Grade 3 or 4 laboratory abnormalities (≥ 2%) were decreased neutrophils, decreased leukocytes, decreased platelets, decreased hemoglobin, decreased potassium, decreased sodium, increased alanine aminotransferase, increased gamma-glutamyl transferase, and decreased albumin. (6.1) Intravenous Amivantamab as a Single Agent The most common adverse reactions (≥ 20%) were rash, infusion-related reaction, paronychia, musculoskeletal pain, dyspnea, nausea, edema, cough, fatigue, stomatitis, constipation, vomiting, and pruritus. (6.1) The most common Grade 3 or 4 laboratory abnormalities (≥ 2%) were increased gamma-glutamyl transferase, decreased sodium, decreased potassium, and increased alkaline phosphatase. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

— FDA label: Rybrevant Faspro, Janssen Biotech, Inc., effective November 5, 2026. This is part of the section. Read the full label on DailyMed →

Amivantamab and hyaluronidase-lpuj (human recombinant) dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

For subcutaneous use only. (2.1) RYBREVANT FASPRO has different recommended dosage and administration than intravenous amivantamab products. (2.1) Administer each injection of RYBREVANT FASPRO subcutaneously in the abdomen over approximately 5 minutes. (2.1) The recommended dosage of RYBREVANT FASPRO is based on baseline body weight. (2.3) Administer premedications as recommended.

Read more of this section

(2.4) RYBREVANT FASPRO has different recommended dosages and dosing schedules based upon the indication and baseline body weight. See dosing Tables 3, 4, and 5. (2.3) 2.1 Important Dosage and Administration Information RYBREVANT FASPRO is for subcutaneous use only. Do not administer RYBREVANT FASPRO intravenously. RYBREVANT FASPRO must be administered by a healthcare professional. To reduce the risk of medication errors, prior to administration, check the vial labels to ensure that the drug being prepared and administered is subcutaneous RYBREVANT FASPRO and not intravenous amivantamab. RYBREVANT FASPRO has different recommended dosage and administration than intravenous amivantamab products. Do not substitute RYBREVANT FASPRO for or with intravenous amivantamab products. Adult patients currently receiving intravenous amivantamab at an every 2-week dosing regimen may switch to subcutaneous RYBREVANT FASPRO at an every 2-week dosing regimen or at an every 4-week dosing regimen at their next scheduled dose on or after Week 5. Adult patients currently receiving intravenous amivantamab at an every 3-week dosing regimen may switch to subcutaneous RYBREVANT FASPRO at an every 3-week dosing regimen at their next scheduled dose on or after Week 4. Adult patients currently receiving RYBREVANT FASPRO at an every 2-week dosing regimen may switch to an every 4-week dosing regimen at their next scheduled dose on or after Week 5. RYBREVANT FASPRO is not indicated for use in pediatric patients. Administer premedications before each RYBREVANT FASPRO dose as recommended, to reduce the risk of administration-related reactions (ARRs) [see Dosage and Administration (2.4)]. For the first dose, monitor patients for hypersensitivity and administration-related reactions for 2 to 4 hours following the end of the injection [see Warnings and Precautions (5.1)]. Administer each injection of RYBREVANT FASPRO subcutaneously in the abdomen over approximately 5 minutes to minimize injection site irritation. Do not inject into tattoos or scars or areas where the skin is red, bruised, tender, hard, not intact or within 2 inches (5 cm) around the periumbilical area. If the total dose requires multiple injections of RYBREVANT FASPRO, administer each injection consecutively in separate quadrants of the abdomen, with each injection taking approximately 5 minutes. Rotate injection sites at the next scheduled dose. Pause or slow the delivery rate if the patient experiences pain. In the event pain is not alleviated by pausing or slowing down delivery rate, a second injection site may be chosen on the opposite side of the abdomen to deliver the remainder of the dose.

Table from the label
IndicationRecommended Dosages and Dosing Schedules
NSCLC, as a single agent or in combination with lazertinibevery 2-week dosing (see Table 3) or every 4-week dosing (see Table 4)
NSCLC, in combination with carboplatin and pemetrexedevery 3-week dosing (see Table 5)
HNSCC, as a single agentevery 4-week dosing (see Table 4) or every 3-week dosing (see Table 5)

— FDA label: Rybrevant Faspro, Janssen Biotech, Inc., effective November 5, 2026. This is part of the section. Read the full label on DailyMed →

Amivantamab and hyaluronidase-lpuj (human recombinant) in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Based on the mechanism of action [see Clinical Pharmacology (12.1)] and findings in animal models, RYBREVANT FASPRO can cause fetal harm when administered to a pregnant woman. There are no available data on the use of RYBREVANT FASPRO in pregnant women or animal data to assess the risk of RYBREVANT FASPRO in pregnancy.

Read more of this section

Disruption or depletion of EGFR in animal models resulted in impairment of embryo-fetal development including effects on placental, lung, cardiac, skin, and neural development. The absence of EGFR or MET signaling has resulted in embryo lethality, malformations, and post-natal death in animals (see Data). Advise pregnant women and females of reproductive potential of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data RYBREVANT FASPRO for subcutaneous injection contains amivantamab and hyaluronidase [see Description (11)]. Amivantamab: No animal studies have been conducted to evaluate the effects of amivantamab on reproduction and fetal development; however, based on its mechanism of action, RYBREVANT FASPRO can cause fetal harm or developmental anomalies. In mice, EGFR is critically important in reproductive and developmental processes including blastocyst implantation, placental development, and embryo-fetal/postnatal survival and development. Reduction or elimination of embryo-fetal or maternal EGFR signaling can prevent implantation, can cause embryo-fetal loss during various stages of gestation (through effects on placental development) and can cause developmental anomalies and early death in surviving fetuses. Adverse developmental outcomes were observed in multiple organs in embryos/neonates of mice with disrupted EGFR signaling. Similarly, knock out of MET or its ligand HGF was embryonic lethal due to severe defects in placental development, and fetuses displayed defects in muscle development in multiple organs. Human IgG1 is known to cross the placenta; therefore, amivantamab has the potential to be transmitted from the mother to the developing fetus. Hyaluronidase: In an embryo-fetal study, mice were dosed daily by subcutaneous injection during the period of organogenesis with hyaluronidase (recombinant human) at dose levels up to 2,200,000 U/kg, which is > 3600 times higher than the human dose. The study found no evidence of teratogenicity. Reduced fetal weight and increased numbers of fetal resorptions were observed, with no effects found at a daily dose of 360,000 U/kg, which is > 600 times higher than the human dose. In a peri-and post-natal reproduction study, mice have been dosed daily by subcutaneous injection, with hyaluronidase (recombinant human) from implantation through lactation and weaning at dose levels up to 1,100,000 U/kg, which is > 1800 times higher than the human dose. The study found no adverse effects on sexual maturation, learning and memory or fertility of the offspring.

— FDA label: Rybrevant Faspro, Janssen Biotech, Inc., effective November 5, 2026. Read the full label on DailyMed →

When Amivantamab and hyaluronidase-lpuj (human recombinant) should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

RYBREVANT FASPRO is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients. Patients with known hypersensitivity to hyaluronidase or to any of its excipients. (4)

— FDA label: Rybrevant Faspro, Janssen Biotech, Inc., effective November 5, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsInjection
RouteSubcutaneous
Prescription products4 in the FDA NDC Directory
Brand namesRybrevant Faspro

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
BLA761433
RYBREVANT FASPRO
Janssen BiotechDecember 17, 2025 1, latest November 5, 2026
2026: Efficacy

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2729297, 2729304, 2729306, 2729307, 2735796, 2735797, 2735803, 2735804
SPL set ID of the quoted label9e58b045-e352-4f62-99bf-77fae1bebc69
FDA labels (SPL)1
FDA applicationsBLA761433
Active ingredients (FDA)AMIVANTAMAB / HYALURONIDASE (HUMAN RECOMBINANT)

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Rybrevant Faspro, Janssen Biotech, Inc., effective November 5, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers